Ceryvyn Therapeutics Ltd
OPT
Rang in Aktien
#31847
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Aktienkurs
$0.00846342
Zuletzt synchronisiert: 2026-07-27
Marktkapitalisierung
$11.27M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-99.75%
Land
AU
Handel Ceryvyn Therapeutics Ltd (OPT)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Ceryvyn Therapeutics Ltd (OPT)
Anzahl der ausstehenden Aktien zum June 2025: 153.78M
Laut den neuesten Finanzberichten und dem Aktienkurs von Ceryvyn Therapeutics Ltd beträgt die aktuelle Anzahl der ausstehenden Aktien 153.78M. Am Ende von June 2024 hatte das Unternehmen 79.78M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Ceryvyn Therapeutics Ltd (OPT) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 153.78M | 0.45% |
| 2025 | 153.09M | 91.90% |
| 2024 | 79.78M | 35.92% |
| 2023 | 58.69M | 25.91% |
| 2022 | 46.62M | 9.71% |
| 2021 | 42.49M | 30.49% |
| 2020 | 32.56M | 11.90% |
| 2019 | 29.10M | 0.27% |
| 2018 | 29.02M | 25.03% |
| 2017 | 23.21M | 7.34% |
| 2016 | 21.62M | 49.48% |
| 2015 | 14.47M | 119.26% |
| 2014 | 6.60M | 8.67% |
| 2013 | 6.07M | -3.84% |
| 2012 | 6.31M | 0.63% |
| 2011 | 6.27M | 2.22% |
| 2010 | 6.14M | 1.38% |
| 2009 | 6.05M | 2.44% |
| 2008 | 5.91M | 0.00% |
| 2007 | 5.91M | 8.57% |
| 2006 | 5.44M | -7.89% |
| 2005 | 5.91M | -0.12% |
| 2004 | 5.92M | 5.63% |
| 2003 | 5.60M | 0.09% |
| 2002 | 5.60M | 7.02% |
| 2001 | 5.23M | 17.30% |
| 2000 | 4.46M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 65.11% |
US
|
|
| 396.00M | 157.51% |
US
|
|
| 478.91M | 211.43% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -59.56% |
NL
|
